Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982 Dec;14(6):799-804.
doi: 10.1111/j.1365-2125.1982.tb02039.x.

Differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R (-)-enantiomer

Clinical Trial

Differences of sympathomimetic and anticholinergic action of OH-maprotiline and its R (-)-enantiomer

O Schmidlin et al. Br J Clin Pharmacol. 1982 Dec.

Abstract

1 C 49802 B-Ba and CGP 12103/A are the racemate and the R (-)-enantiomer respectively of the hydroxylated derivative of the tetracyclic antidepressant maprotiline, which differed in their ability to block noradrenaline-uptake and in their anticholinergic activity in animal models. 2 The sympathomimetic and anticholinergic activities of both substances were evaluated in eight healthy subjects and compared with the treatment with placebo and amitriptyline. 3 Heart rate, pupillary diameter, stimulated salivary flow rate and blood pressure were measured over a 15 h period keeping a very strict protocol. Plasma catecholamine levels were determined. 4 Saliva production was diminished following the administration of C 49802 B-Ba, CGP 12103/A and amitriptyline. 5 A moderate, but significant increase in heart rate and mean arterial blood pressure in the recumbent position was observed when C 49802 B-Ba was given. 6 The results in man are in agreement with the different activities found in animal experiments. 7 It can be concluded that the S (+)-enantiomer which the racemate contains is more active than the R (-)-enantiomer as to the anticholinergic and the sympathomimetic property.

PubMed Disclaimer

References

    1. Psychosom Med. 1975 Mar-Apr;37(2):160-79 - PubMed
    1. Life Sci. 1976 Oct 15;19(8):1161-74 - PubMed
    1. Eur J Pharmacol. 1977 Dec 15;46(4):387-91 - PubMed
    1. JAMA. 1978 Jan 16;239(3):213-6 - PubMed
    1. Br J Clin Pharmacol. 1978;5 Suppl 1:29S-34S - PubMed

Publication types

LinkOut - more resources